Kamgar F, Ho S, Hawe E, Brodtkorb TH. A review of treatment effect waning methods for immuno-oncology therapies in National Institute for Health and Care Excellence technology appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S98. doi: 10.1016/j.jval.2022.09.476
Kamgar F, Thybo SH, Johannesen K, Teitsson S, Brodtkorb TH. Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence with tumor cell pd-l1 expression ≥ 1% in Denmark. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.706
Kamgar F, Johannesen K, Thybo SH, Teittson S, Brodtkorb TH. Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell pd-l1 expression ≥ 1% in Sweden. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.707
Hancock H, Brockbank J, Theodorou E, Brodtkorb TH. Survival analysis methods used in immuno-oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S92. doi: 10.1016/j.jval.2022.09.451
Hancock H, Brockbank J, Brodtkorb TH, Lucherini S, Russell J. A review of cure assumptions implemented in early-stage oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S148. doi: 10.1016/j.jval.2022.09.714
Brodtkorb TH. Does the choice of cost-effectiveness model approach matter? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.
Earnshaw S, Brogan A, Brodtkorb TH, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2022 Virtual ISPOR Short Course Program; September 21, 2022. Previously presented at the 2021 Virtual ISPOR Short Course Program.
Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382